GILEAD SCIENCES, INC

GILD
Delayed Quote. Delayed  - 11/24 04:00:00 pm
60.25USD +0.60%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 22 44923 650
EBITDA1 12 46812 633
Operating profit (EBIT)1 11 06411 163
Operating Margin 49,3%47,2%
Pre-Tax Profit (EBT)1 5 1601 465
Net income1 5 38634,3
Net margin 24,0%0,15%
EPS2 4,22-0,01
Dividend per Share2 2,522,73
Last update 02/04/202011/20/2020
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 24120 525
Net Cash position1 --
Leverage (Debt / EBITDA) 0,02x1,62x
Free Cash Flow1 8 3197 053
ROE (Net Profit / Equities) 38,3%33,0%
Shareholders' equity1 14 055104
ROA (Net Profit / Asset) 8,60%-0,20%
Assets1 62 651-17 147
Book Value Per Share2 17,816,9
Cash Flow per Share2 7,167,70
Capex1 825795
Capex / Sales 3,67%3,36%
Last update 02/04/202011/20/2020
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 75 525 M $ -
Entreprise Value (EV) 96 050 M $ 91 643 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) -4 420x 10,7x
Capitalization / Revenue 3,19x 3,19x
EV / Revenue 4,06x 4,06x
EV / EBITDA 7,60x 7,68x
Yield (DPS / Price) 4,52% 4,68%
Price to book (Price / BVPS) 3,56x 3,13x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 47,2% 47,0%
Operating Leverage (Delta EBIT / Delta Sales) 0,17x -
Net Margin (Net Profit / Revenue) 0,15% 30,5%
ROA (Net Profit / Asset) -0,20% 10,4%
ROE (Net Profit / Equities) 33,0% 28,8%
Rate of Dividend -20 000% 49,9%
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   3,36% 3,19%
Cash Flow / Sales 40,8% 36,6%
Capital Intensity (Assets / Sales) -0,73x 2,93x
Financial Leverage (Net Debt / EBITDA) 1,62x 1,29x
Price Earning Ratio
EPS & Dividend